Skip to main content
SpringerLink
Log in

Mind-mapping for lung cancer: Towards a personalized therapeutics approach

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

There were over 220,000 people diagnosed with lung cancer and over 160,000 people dying of lung cancer during 2010 alone in the United States. In order to arrive at better control, prevention, diagnosis, and therapeutics for lung cancer, we must be able to personalize the approach towards the disease. Mind-mapping has existed for centuries for physicians to properly think about various “flows” of personalized medicine. We include here the epidemiology, diagnosis, histology, and treatment of lung cancer—in particular, non-small cell lung cancer. As we have new molecular signatures for lung cancer, this is further detailed. This review is not meant to be a comprehensive review, but rather its purpose is to highlight important aspects of lung cancer diagnosis, management, and personalized treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Buzan T, Buzan B. The Mind Map Book. London: BBC Books; 1993.

    Google Scholar 

  2. D'Antoni AV, Zipp GP, Olson VG, Cahill TF. Does the mind map learning strategy facilitate information retrieval and critical thinking in medical students? BMC Med Educ. 2010;10:61.

    Article  PubMed  Google Scholar 

  3. Farrand P, Hussain F, Hennessy E. The efficacy of the ‘mind map’ study technique. Med Educ. 2002;36:426–431.

    Article  PubMed  Google Scholar 

  4. Wickramasinghe A, Widanapathirana N, Kuruppu O, Liyanage I, Karunathilake I. Effectiveness of mind maps as a learning tool for medical students. South East Asian J Med Educ. 2007;1:30–32.

    Google Scholar 

  5. Eppler MJ. A comparison between concept maps, mind maps, conceptual diagrams, and visual metaphors as complementary tools for knowledge construction and sharing. Information Visualization. 2006;5:202–210.

    Article  Google Scholar 

  6. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2007, National Cancer Institute; Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Accessed September 28, 2010.

  7. Cancer Facts and Figures 2010. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf. Accessed September 28, 2010.

  8. Health Service, Centers for Disease Control and Prevention, Washington, DC 2010. Smoking and tobacco use-fact sheets. Available at: http://www.cdc.gov/tobacco/data_statistics/fact_sheets/. Accessed May 4, 2010.

  9. Alberg AJ, Nonemaker J. Who is at high risk for lung cancer? Population-level and individuallevel perspectives. Semin Respir Crit Care Med. 2008;29:223–232.

    Article  PubMed  Google Scholar 

  10. Burns, DM. Cigarette smoking. In: Comprehensive Textbook of Thoracic Oncology, Aisner J, et al (eds), Williams and Wilkins; Baltimore 1996:51.

    Google Scholar 

  11. US Department of Health and Human Services. The Health Benefits of Smoking Cessation: a Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1990. Available at http://www.hhs.gov/. Accessed April 5, 2010.

    Google Scholar 

  12. Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA 2005;294:1505–1510.

    Article  PubMed  CAS  Google Scholar 

  13. Shaten BJ, Kuller LH, Kjelsberg MO, et al. Lung cancer mortality after 16 years in MRFIT participants in intervention and usual-care groups. Multiple Risk Factor Intervention Trial. Ann Epidemiol. 1997;7:125–136.

    Article  PubMed  CAS  Google Scholar 

  14. Han B, Gfroerer JC, Colliver JD. Associations between duration of illicit drug use and health conditions: results from the 2005–2007 National Surveys on Drug Use and Health. Ann Epidemiol. 2010;20:289–297.

    Article  PubMed  Google Scholar 

  15. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. Br Med J. 1997;315:980–988.

    CAS  Google Scholar 

  16. Brüske-Hohlfeld, I. Environmental and occupational risk factors for lung cancer. Methods Mol Biol. 2009;472:3–23.

    Article  PubMed  Google Scholar 

  17. American Cancer Society. What causes small cell lung cancer? Available at: http://www.cancer.org/. Accessed May 19, 2010.

  18. National Cancer Institute. Asbestos exposure and cancer risk. Available at: http://www.cancer.gov/cancertopics/factsheet/Risk/asbestos. Accessed May 20, 2010.

  19. van Loon AJ, Goldbohm RA, Kant IJ, Swan GMH, Kremer AM, van den Brandt PA. Socioeconomic status and lung cancer incidence in men in the Netherlands: is there a role for occupational exposure? J Epidemiol Community Health. 1997;51:24–29.

    Article  PubMed  Google Scholar 

  20. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. Br J Cancer. 2005;93:825–833.

    Article  PubMed  CAS  Google Scholar 

  21. Prochazka M, Hall P, Gagliardi G, et al. Ionizing radiation and tobacco use increases the risk of a subsequent lung carcinoma in women with breast cancer: case-only design. J Clin Oncol. 2005;23:7467–7474.

    Article  PubMed  Google Scholar 

  22. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497–1505.

    Article  PubMed  CAS  Google Scholar 

  23. Yang P, Sun Z, Krowka MJ, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med. 2008;168:1097–1103.

    Article  PubMed  Google Scholar 

  24. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A populationbased cohort study. Am J Respir Crit Care Med. 2000;161:5–8.

    PubMed  CAS  Google Scholar 

  25. Goodman GE, Thornquist MD, Balmes J, et al. The beta-carotene and retinol efficacy trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping betacarotene and retinol supplements. J Natl Cancer Inst. 2004;96:1743–1750.

    Article  PubMed  CAS  Google Scholar 

  26. Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis. 1984;130:561–565.

    PubMed  CAS  Google Scholar 

  27. Kubík A, Polák J. Lung cancer detection. Results of a randomized prospective study in Czechloslovakia. Cancer. 1986;57:2427–2437.

    Article  PubMed  Google Scholar 

  28. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest. 1984;86:44–53.

    Article  PubMed  CAS  Google Scholar 

  29. National Lung Screening Trial (NLST). Available at: http://clinicaltrials.gov/. Accessed May 26, 2010.

  30. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120:868–874.

    Article  PubMed  CAS  Google Scholar 

  31. Steiling K, Ryan J, Brody JS, Spira A. The field of tissue injury in the lung and airway. Cancer Prev Res. 2008;1:396–403.

    Article  CAS  Google Scholar 

  32. Roy HK, Subramanian H, Damania D, et al. Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res. 2010;70:7748–7754.

    Article  PubMed  CAS  Google Scholar 

  33. van den Bergh KA, Essink-Bot ML, Borsboom GJ, et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON). Br J Cancer. 2010;102:27–34.

    Article  PubMed  Google Scholar 

  34. Reich JM. A critical appraisal of overdiagnosis: estimates of its magnitude and implications for lung cancer screening. Thorax. 2008;63:377–383.

    Article  PubMed  CAS  Google Scholar 

  35. Bach P. Overdiagnosis in lung cancer: different perspectives, definitions, implications. Thorax. 2008;63:298–300.

    Article  PubMed  Google Scholar 

  36. Travis WD, Brambilla E, Muller-Hermlink HK, Harris CC, eds. World Health Organization classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.

  37. Rodenhuis S, Slebos RJC, Boot AJM, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1988;48:5738–5741.

    PubMed  CAS  Google Scholar 

  38. Barsky SH, Grossman DA, Ho J, Holmes EC. The multifocality of bronchioloalveolar lung carcinoma: evidence and implications of a multiclonal origin. Mod Pathol. 1994;7:633–640.

    PubMed  CAS  Google Scholar 

  39. Breathnach OS, Kwiatkowski DJ, Finkelstein DM, et al. Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease. J Thorac Cardiovasc Surg. 2001;121:42–47.

    Article  PubMed  CAS  Google Scholar 

  40. Barsky SH, Cameron R, Osann KE, Tomita D, Holmes EC. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer. 1994;73:1163–1170.

    Article  PubMed  CAS  Google Scholar 

  41. Liebow, AA. Bronchiolo-alveolar carcinoma. Adv Intern Med. 1960;10:329–358.

    PubMed  CAS  Google Scholar 

  42. Wang YC, Chen CY, Chen SK, Cherng SH, Ho WL, Lee H. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Cancer Res. 1998;58:328–333.

    PubMed  CAS  Google Scholar 

  43. Maziak De, Darling GE, Inculet RI, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med. 2009;151:221–228.

    PubMed  Google Scholar 

  44. Luke WP, Pearson FG, Todd TR, et al. Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung. J Thorac Cardiovasc Surg. 1986;91:53–56.

    PubMed  CAS  Google Scholar 

  45. Vilmann P, Krasnick M, Larsen SS, Jacobsen GK, Clementsen P. Transesophageal endoscopic ultrasound-guided fine needle aspiration (EUSFNA) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS): a combined approach in the evaluation of mediastinal lesions. Endoscopy. 2005;37:833–839.

    Article  PubMed  CAS  Google Scholar 

  46. National Comprehensive Cancer Network (NCCN) Guidelines in Oncology: Non-Small Cell Carcinoma. Available at: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed August 20, 2010.

  47. Schwartz AM, Henson DE. Diagnostic surgical pathology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(suppl. 3):78S–93S.

    Article  PubMed  Google Scholar 

  48. Ou SH, Zell JA, Anton-Culver H. Prognostic factors for survival of stage 1 nonsmall cell lung cancer patients: a population based analysis of 19, 702 stage 1 patients in the California Cancer Registry from 1989 to 2003. Cancer. 2007;110:1532–1541.

    Article  PubMed  Google Scholar 

  49. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(suppl. 3):234S–242S.

    Article  PubMed  Google Scholar 

  50. Doddoli C, D'Journo B, Le Pimpec-Barthes F, et al. Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies. Ann Thorac Surg. 2005;80:2032–2040.

    Article  PubMed  Google Scholar 

  51. Arriagada R, Bergman B, Dunant A, et al. Cisplatinbased adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360.

    Article  PubMed  Google Scholar 

  52. Daniels LJ, Balderson SS, Onaitis MW, et al. Thoracoscopic lobectomy: a safe and effective strategy for patients with stage I lung cancer. Ann Thorac Surg. 2002;74:860–864.

    Article  PubMed  Google Scholar 

  53. Mckenna RJ, Houck W, Fuller CB. Video-assisted thoracic surgery lobectomy: experience with 1,100 cases. Ann Thorac Surg. 2006;81:421–426.

    Article  PubMed  Google Scholar 

  54. Watanabe Y, Shimizu J, Hayashi Y, et al. Results of surgical treatment on patients with stage IIIA non-small lung cancer. Thorac Cardiovasc Surg. 1991;39:44–49.

    Article  PubMed  CAS  Google Scholar 

  55. Johnstone DW, Byhardt RW, Ettinger D, et al. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Intern J Radiat Oncol Biol Phys. 2002;54:365–369.

    Article  Google Scholar 

  56. Taylor NA, Liao ZX, Cox JD, et al. Equivalent outcome of patients with clinical stage IIIA nonsmall cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by resection. Int J Radiat Oncol Biol Phys. 2004;58:204–212.

    Article  PubMed  Google Scholar 

  57. van Meerbeeck JP, Kramer GW, Van Schil PE, et al; European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99:442–450.

    Article  PubMed  Google Scholar 

  58. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW; American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(suppl. 3):243S–265S.

    Article  PubMed  Google Scholar 

  59. Patterson GA, Piazza D, Pearson FG, et al. Significance of metastatic disease in subaortic lymph nodes. Ann Thorac Surg. 1987;43:155–159.

    Article  PubMed  CAS  Google Scholar 

  60. Watanabe Y, Hayashi Y, Shimizu J, Oda M, Iwa T. Mediastinal nodal involvement and the prognosis of non-small cell lung cancer. Chest. 1991;100:422–428.

    Article  PubMed  CAS  Google Scholar 

  61. Pairolero PC, Trastek VF, Payne WS. Treatment of bronchogenic carcinoma with chest wall invasion. Surg Clin North Am. 1987;67:959–964.

    PubMed  CAS  Google Scholar 

  62. Piehler JM, Pairolero PC, Weiland LH, Offord KP, Payne WS, Bernatz PE. Bronchogenic carcinoma with chest wall invasion: factors affecting survival following en bloc resection. Ann Thorac Surg. 1982;34:684–691.

    Article  PubMed  CAS  Google Scholar 

  63. Harpole DH Jr, Healey EA, DeCamp MM Jr, Mentzer SJ, Strauss GM, Sugarbaker DJ. Chest wall invasive non-small cell lung cancer: patterns of failure and implications for a revised staging system. Ann Surg Oncol. 1996;3:261–269.

    Article  PubMed  Google Scholar 

  64. McCaughan BC, Martini N, Bains MS, McCormack PM. Chest wall invasion in carcinoma of the lung. Therapeutic and prognostic implications. J Thorac Cardiovasc Surg. 1985;89:836–841.

    PubMed  CAS  Google Scholar 

  65. Port JL, Korst RJ, Lee PC, Kansler AL, Kerem Y, Altorki NK. Surgical resection for multifocal (T4) non-small cell lung cancer: is the T4 designation valid? Ann Thorac Surg. 2007;83:397–400.

    Article  PubMed  Google Scholar 

  66. Osaki T, Sugio K, Hanagiri T, et al. Survival and prognostic factors of surgically resected T4 non-small cell lung cancer. Ann Thorac Surg. 2003;75:1745–1751.

    Article  PubMed  Google Scholar 

  67. Nagai K, Sohara Y, Tsuchiya R, Goya T, Miyaoka E; Japan Lung Cancer Registration Committee. Prognosis of resected non-small cell lung cancer patients with intrapulmonary metastases. J Thorac Oncol. 2007;2:282–286.

    Article  PubMed  Google Scholar 

  68. de Perrot M, Fadel E, Mussot S, de Palma A, Chapelier A, Dartevelle P. Resection of locally advanced (T4) non-small cell lung cancer with cardiopulmonary bypass. Ann Thorac Surg. 2005;79:1691–1696.

    Article  PubMed  Google Scholar 

  69. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880–1892.

    PubMed  CAS  Google Scholar 

  70. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007;25:313–318.

    Article  PubMed  Google Scholar 

  71. Komaki R, Mountain CF, Holbert JM, et al. Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation. Int J Radiat Oncol Biol Phys. 1990;19:31–36.

    Article  PubMed  CAS  Google Scholar 

  72. Mountain CF. Expanded possibilities for surgical treatment of lung cancer: survival in stage IIIA disease. Chest. 1990;97:1045–1051.

    Article  PubMed  CAS  Google Scholar 

  73. Hu C, Chang EL, Hassenbusch SJ 3rd, et al. Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis Cancer. 2006;106:1998–2004.

    Article  PubMed  Google Scholar 

  74. Mintz A, Perry J, Spithoff K, Chambers A, Laperriere N. Management of single brain metastasis: a practice guideline. Curr Oncol. 2007;14:131–143.

    Article  PubMed  CAS  Google Scholar 

  75. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500.

    Article  PubMed  CAS  Google Scholar 

  76. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483–2491.

    Article  PubMed  CAS  Google Scholar 

  77. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring EML4-ALK. J Clin Oncol. 2009;27:4247–4253.

    Article  PubMed  CAS  Google Scholar 

  78. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432–1440.

    Article  PubMed  CAS  Google Scholar 

  79. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27:6251–6266.

    Article  PubMed  CAS  Google Scholar 

  80. West H, Lilenbaum R, Harpole D, Wozniak A, Sequist L. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol. 2009;4(9 suppl. 2):S1029–S1039.

    Article  PubMed  Google Scholar 

  81. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med. 1987;317:929–935.

    Article  PubMed  CAS  Google Scholar 

  82. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991;6:1353–1362.

    PubMed  CAS  Google Scholar 

  83. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990;323:561–565.

    Article  PubMed  CAS  Google Scholar 

  84. Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst. 1999;91:2032–2038.

    Article  PubMed  CAS  Google Scholar 

  85. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008;14:5731–5734.

    Article  PubMed  CAS  Google Scholar 

  86. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005;92:131–139.

    Article  PubMed  CAS  Google Scholar 

  87. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern cooperative oncology group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol. 2001;19:448–457.

    PubMed  CAS  Google Scholar 

  88. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-smallcell lung cancer. J Clin Oncol. 1999;17:668–675.

    PubMed  CAS  Google Scholar 

  89. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007;25:5240–5247.

    Article  PubMed  Google Scholar 

  90. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008;26:1472–1478.

    Article  PubMed  CAS  Google Scholar 

  91. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900–5909.

    Article  PubMed  CAS  Google Scholar 

  92. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer. 2003;41(suppl. 1):S29–S42.

    Article  PubMed  Google Scholar 

  93. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139.

    Article  PubMed  CAS  Google Scholar 

  94. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500.

    Article  PubMed  CAS  Google Scholar 

  95. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2006;118:257–262.

    Article  PubMed  CAS  Google Scholar 

  96. Pietanza M, D'Angelo SP, Johnson ML, et al. EGFR mutations in men and cigarette smokers with lung adenocarcinoma [abstract]. Clin Oncol. 2010;28(suppl.):15S. Abstract 10538.

    Google Scholar 

  97. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science. 2007;98:1817–1824.

    Article  PubMed  CAS  Google Scholar 

  98. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005;2:e313.

    Article  PubMed  CAS  Google Scholar 

  99. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005;65:226–235.

    PubMed  CAS  Google Scholar 

  100. Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006;9:485–495.

    Article  PubMed  CAS  Google Scholar 

  101. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res. 2000;6:2349–2355.

    PubMed  CAS  Google Scholar 

  102. Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep. 2000;7:603–607.

    PubMed  CAS  Google Scholar 

  103. Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer. 1998;77:663–669.

    Article  PubMed  CAS  Google Scholar 

  104. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer. 2004;91:208–212.

    PubMed  CAS  Google Scholar 

  105. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol. 1997;15:2858–2865.

    PubMed  CAS  Google Scholar 

  106. Pfeiffer P, Clausen PP, Andersen K, Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-smallcell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 1996;74:86–91.

    Article  PubMed  CAS  Google Scholar 

  107. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 1997;3:515–522.

    PubMed  CAS  Google Scholar 

  108. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545–1552.

    Article  PubMed  CAS  Google Scholar 

  109. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892–5899.

    Article  PubMed  CAS  Google Scholar 

  110. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial — INTACT 1. J Clin Oncol. 2004;22:777–784.

    Article  PubMed  CAS  Google Scholar 

  111. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial — INTACT 2. J Clin Oncol. 2004;22:785–794.

    Article  PubMed  CAS  Google Scholar 

  112. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2006;24:3831–3837.

    Article  PubMed  CAS  Google Scholar 

  113. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132.

    Article  PubMed  CAS  Google Scholar 

  114. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169–181.

    Article  PubMed  CAS  Google Scholar 

  115. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in nonsmall cell lung cancer. Nature. 2007;448:561–566.

    Article  PubMed  CAS  Google Scholar 

  116. Takahashi T, Sonobe M, Koboyashi M, et al. Clinicopathologic features of non-small cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17:889–897.

    Article  PubMed  Google Scholar 

  117. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115:1723–1733.

    Article  PubMed  CAS  Google Scholar 

  118. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14:4275–4283.

    Article  PubMed  CAS  Google Scholar 

  119. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190–1203.

    Article  PubMed  CAS  Google Scholar 

  120. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3:13–17.

    Article  PubMed  Google Scholar 

  121. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22:508–515.

    Article  PubMed  CAS  Google Scholar 

  122. Hwang SJ, Cheng LS, Lozano G, Amos CI, Gu X, Strong LC. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet. 2003;113:238–243.

    Article  PubMed  CAS  Google Scholar 

  123. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA. 2008;105:19893–19897.

    Article  PubMed  CAS  Google Scholar 

  124. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic largecell lymphoma. Mol Cancer Ther. 2007;6:3314–3322.

    Article  PubMed  CAS  Google Scholar 

  125. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008;68:3389–3395.

    Article  PubMed  CAS  Google Scholar 

  126. Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer [abstract]. J Clin Oncol. 2010;28:946S. Abstract 3.

    Google Scholar 

  127. National Institutes of Health Clinical Trials database. Available at: http://www.clinicaltrials.gov/. Accessed July 7, 2010.

  128. Mento AJ, Martinelli P, Jones RM. Mind mapping in executive education: Applications and outcomes. Journal of Management Development. 1999;18:390–407.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of General Surgery, University of Illinois at Mount Sinai Hospital, Chicago, IL, 60608, USA

    N. Mollberg

  2. Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, 60637, USA

    M. Surati, C. Demchuk & R. Fathi

  3. Department of Medicine, Section of Medical Oncology, Duke University Medical Center, Durham, NC, 27710, USA

    A. K. Salama

  4. Department of Pathology, University of Chicago, Chicago, IL, 60637, USA

    A. N. Husain

  5. Department of Medicine, Section of Hematology/Oncology, Northshore University HealthSystem, Evanston, IL, 60201, USA

    T. Hensing

  6. Department of Medicine, Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL, 60637, USA

    R. Salgia

Authors
  1. N. Mollberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Surati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Demchuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Fathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. K. Salama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. N. Husain
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Hensing
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R. Salgia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Salgia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mollberg, N., Surati, M., Demchuk, C. et al. Mind-mapping for lung cancer: Towards a personalized therapeutics approach. Adv Therapy 28, 173–194 (2011). https://doi.org/10.1007/s12325-010-0103-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0103-9

Keywords

Search

Navigation